# CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

> **NCT03896854** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd** · enrollment: 15 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CART-19

## Key facts

- **NCT ID:** NCT03896854
- **Lead sponsor:** Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-18
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03896854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03896854, "CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03896854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*